Sign in
Taking people in United StatesPhase 2

Radiation That Spares Healthy Brain Tissue for People With Brain Metastases

Studies quality of life and symptoms after sparing-style brain radiation in adults with brain metastases.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
NTS-WBRT in Brain Metastases
Status
Recruiting
Phase
Phase 2
People taking part
41 people, planned
Started
8 Feb 2022
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • NTS-WBRT (normal tissue sparing whole brain radiation therapy)
  • Memantine
Record updated
16 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid tumor that has spread to the brain, who need whole brain radiation. It studies quality of life and symptoms after a brain radiation that spares normal tissue, given with memantine.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Any number of brain metastases (cancer spread to the brain) from a solid tumor, needing whole brain radiation. Karnofsky Performance Status (a score of daily functioning) of 70 or more. Expected survival of more than 6 months.
Earlier treatment
Earlier focused radiation (SRS) or brain surgery may be allowed if the doctor agrees. Radiation starts at least 2 weeks after brain surgery. Earlier partial brain radiation is allowed if it covered less than 50% of the brain. People who had whole brain radiation before cannot join. Other cancer drugs before, during or after are allowed if the doctors agree.
Biomarker or test result
Women before menopause need a negative pregnancy test.

Main reasons for not taking part

  • Cancer spread to the lining of the brain and spinal cord (leptomeningeal disease).
  • Earlier whole brain radiation.
  • Past or current use of memantine or other NMDA antagonists.
  • Allergy to MRI contrast or unable to have an MRI.
  • Pregnancy, or not willing to use birth control during radiation.

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy
  • Age ≥ 18
  • Karnofsky Performance Status ≥ 70
  • Prior stereotactic radiosurgery (SRS) permissible per physician discretion
  • Prior craniotomy permissible per physician discretion. Protocol radiation therapy should be initiated ≥2 weeks after craniotomy
  • Prior partial brain radiation therapy permissible if target volume < 50% brain and per physician discretion
  • Expectant > 6 months survival
  • Ability to understand and the willingness to sign a written informed consent document
  • Fluency in English, able to complete questionnaires and neurocognitive testing
  • Ability to undergo MRI with gadolinium examination
  • Ability to return for follow-up examinations throughout the course of this study for a maximum of 2 years after radiation treatment completion
  • Any prior, concomitant, or post-radiotherapy systemic therapy is permitted at discretion of treating physicians
  • Negative pregnancy test for premenopausal women

Who cannot take part

  • Prior whole brain radiation therapy
  • Uncontrolled intercurrent illness that could significantly affect baseline cognitive function as determined by the enrolling clinician, such as symptomatic congestive heart failure, unstable angina pectoris, prior CVA, significant uncontrolled epilepsy or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or unwilling to use appropriate contraception to prevent pregnancy during the time of radiation therapy
  • Concurrent participation in an investigational systemic therapy protocol
  • Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study)
  • Known allergy to contrast used in imaging studies and/or inability to have MRI imaging
  • Pre-existing or current use of memantine or other NMDA antagonists

This trial is currently available in United States.

  • Massachusetts General Hospital Cancer CenterBoston, United StatesContact: Helen A Shih, MD,MS,MPHTaking people

About the trial

What the trial wants to find out

This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT).

Read full original descriptionShow less

This research study involves:

* NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug

The group in the trial

  • NTS-WBRT (normal tissue sparing whole brain radiation therapy) + MemantineTreatment being tested

    Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive: * NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks. * Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor

    Treatment: NTS-WBRT (normal tissue sparing whole brain radiation therapy) and Memantine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) in Patients With Brain Metastases
Plain-language title
Radiation That Spares Healthy Brain Tissue for People With Brain MetastasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
16 April 2026